INCB 3284

Drug Profile

INCB 3284

Alternative Names: INCB3284

Latest Information Update: 28 May 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Incyte Corporation
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action CCR2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Insulin resistance; Rheumatoid arthritis

Most Recent Events

  • 23 Nov 2005 Incyte and Pfizer have entered into an exclusive worldwide agreement for the development, manufacture and marketing of INCB 3284 and other CCR2 antagonists
  • 08 Aug 2005 Phase-II clinical trials in Insulin resistance in USA (PO)
  • 04 May 2005 Phase-II clinical trials in Rheumatoid arthritis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top